LGND
LIGAND PHARMACEUTICALS INCCompany Information
- Company Name
- LIGAND PHARMACEUTICALS INC
- CIK
- CIK0000886163
- Category
- Large accelerated filer
- Ticker: Exchange
- LGND: Nasdaq, LGNDZ: OTC, LGNXZ: OTC, LGNYZ: OTC, LGNZZ: OTC
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- LGND
SEC filing data through
Insider Sentiment
- Last purchase
- 2025-05-09
- Last sale
- 2026-09-10
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 141,749
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 22,190,188
- Shares outstanding
- 20,063,000
- Ownership
- 110.60%
Earnings Market Reaction
- Filing date
- 2026-08-07
- Price on filing date
- —
- 1-month reaction
- -4.32%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 1,007 | 115 | 175 | 139 | 68 | 48 | 72 | 64 | 18 | 50 | 23 | 19 | ||||||
| Short Term Investments | 351 | 664 | 559 | 525 | 177 | 161 | 184 | 156 | 209 | 261 | 147 | 171 | ||||||
| Accounts Receivable Net Current | 67 | 53 | 60 | 58 | 41 | 38 | 38 | 34 | 37 | 28 | 33 | 36 | ||||||
| Inventory Net | 10 | 13 | 9 | 12 | 15 | 15 | 14 | 17 | 19 | 21 | 24 | 25 | ||||||
| Prepaid Expense Current | - | - | - | - | - | - | 2 | - | 2 | 1 | 1 | - | ||||||
| Income Taxes Receivable | 3 | 1 | 1 | 1 | 1 | 4 | 4 | 8 | 0 | 0 | 6 | 0 | ||||||
| Derivative Assets Current | - | - | - | - | - | - | - | 11 | 20 | - | - | - | ||||||
| Other Assets Current | 6 | 6 | 6 | 7 | 5 | 13 | 9 | 20 | 7 | 7 | 3 | 2 | ||||||
| Assets Held For Sale Not Part Of Disposal Group Current | - | - | - | - | 35 | 30 | - | - | - | - | - | - | ||||||
| Assets Current | 1,457 | 865 | 832 | 754 | 353 | 309 | 332 | 309 | 312 | 369 | 237 | 254 | ||||||
| Intangible Assets Net Excluding Goodwill | 209 | 217 | 225 | 234 | 250 | 258 | 267 | 275 | 283 | 291 | 300 | 315 | ||||||
| Goodwill | 102 | 102 | 102 | 102 | 102 | 102 | 105 | 105 | 105 | 105 | 103 | 104 | ||||||
| Derivative Assets Noncurrent | 18 | 14 | 16 | 9 | 18 | 18 | 11 | 19 | 35 | - | 4 | - | ||||||
| Property Plant And Equipment Net | - | 3 | 4 | 3 | 4 | 4 | 15 | 15 | 15 | 15 | 16 | 16 | ||||||
| Equity Method Investments | 42 | 32 | 47 | 42 | - | - | 0 | 1 | 2 | 10 | 13 | 14 | ||||||
| Equity Securities F V N I Noncurrent | - | - | - | - | - | - | - | - | - | - | - | 33 | ||||||
| Operating Lease Right Of Use Asset | - | 7 | 5 | 8 | 8 | 7 | 7 | 7 | 7 | 6 | 6 | 6 | ||||||
| Other Investments | 114 | 88 | 121 | 107 | 11 | 11 | 11 | 12 | 11 | 37 | 37 | - | ||||||
| Deferred Income Tax Assets Net | 37 | 8 | 8 | 10 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 9 | ||||||
| Finance Lease Right Of Use Asset | - | - | - | - | - | - | 3 | 3 | 3 | 3 | 3 | 4 | ||||||
| Other Assets Noncurrent | 12 | 13 | 13 | 3 | 9 | 8 | 32 | 8 | 12 | 11 | 6 | 8 | ||||||
| Assets | 2,186 | 1,532 | 1,561 | 1,477 | 949 | 905 | 942 | 955 | 866 | 914 | 787 | 769 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 9 | 5 | 3 | 4 | 9 | 5 | 5 | 5 | 2 | 2 | 2 | 2 | ||||||
| Accrued Liabilities Current | 32 | 32 | 31 | 24 | 17 | 24 | 28 | 16 | 12 | 12 | 12 | 11 | ||||||
| Taxes Payable Current | 3 | 2 | 1 | 1 | 0 | 2 | 1 | 2 | 2 | 1 | - | 1 | ||||||
| Operating Lease Liability Current | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | ||||||
| Finance Lease Liability Current | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | ||||||
| Liabilities Of Disposal Group Including Discontinued Operation | - | - | - | - | 36 | 26 | - | - | - | - | - | - | ||||||
| Other Liabilities Current | 1 | 0 | 0 | 0 | - | - | 1 | - | - | - | - | 1 | ||||||
| Liabilities Current | 47 | 41 | 37 | 31 | 65 | 59 | 37 | 25 | 19 | 18 | 17 | 16 | ||||||
| Deferred Revenue Noncurrent | - | - | - | - | - | - | - | - | - | - | 1 | - | ||||||
| Contract With Customer Liability Current | - | - | 1 | - | 0 | 0 | 1 | 1 | 1 | 1 | 1 | - | ||||||
| Convertible Debt Current | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Deferred Income Noncurrent | - | - | 0 | 0 | 0 | 0 | 2 | 3 | 3 | 3 | 1 | - | ||||||
| Operating Lease Liability Noncurrent | 4 | 4 | 4 | 4 | 5 | 4 | 6 | 6 | 6 | 5 | 6 | 6 | ||||||
| Senior Long Term Notes | 1,127 | 447 | 446 | 445 | - | - | 0 | - | - | - | - | - | ||||||
| Deferred Income Tax Liabilities Net | 22 | 23 | 36 | 23 | 32 | 29 | 33 | 46 | 30 | 51 | 32 | 33 | ||||||
| Other Liabilities Noncurrent | 17 | 17 | 17 | 20 | 14 | 14 | 30 | 30 | 29 | 28 | 28 | 44 | ||||||
| Liabilities | 1,218 | 535 | 543 | 527 | 120 | 110 | 111 | 114 | 91 | 107 | 86 | 101 | ||||||
Stockholders Equity | ||||||||||||||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 380 | 397 | 401 | 363 | 359 | 341 | 337 | 309 | 239 | 218 | 199 | 184 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | 4 | 5 | 8 | 9 | 8 | -2 | -6 | 2 | -1 | -1 | -1 | -1 | ||||||
| Retained Earnings Accumulated Deficit | 583 | 595 | 608 | 578 | 461 | 457 | 499 | 530 | 537 | 589 | 503 | 485 | ||||||
| Stockholders Equity | 968 | 997 | 1,017 | 950 | 827 | 796 | 830 | 841 | 775 | 807 | 701 | 668 | ||||||
| Liabilities And Stockholders Equity | 2,186 | 1,532 | 1,561 | 1,477 | 949 | 905 | 942 | 955 | 866 | 914 | 787 | 769 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 60 | 60 | 60 | 60 | 60 | 60 | 60 | 60 | 60 | 60 | 60 | 60 | ||||||
| Common Stock Shares Issued | 20 | 20 | 20 | 20 | 19 | 19 | 19 | 19 | 18 | 18 | 18 | 17 | ||||||
| Shares Outstanding | 20 | 20 | 20 | 20 | 19 | 19 | 19 | 19 | 18 | 18 | 18 | 17 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialLIGAND PHARMACEUTICALS INC (LGND) — SEC Financial Statements & Analysis
LIGAND PHARMACEUTICALS INC (LGND) is a pharmaceutical preparations company, incorporated in DE. LIGAND PHARMACEUTICALS INC trades on Nasdaq, OTC as: LGND, LGNDZ, LGNXZ, LGNYZ, LGNZZ. LIGAND PHARMACEUTICALS INC (LGND)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-07. Based on that filing, LIGAND PHARMACEUTICALS INC carries a market cap of $6.34B, a P/E ratio of 32.16x, a P/B ratio of 6.55x, a P/S ratio of 21.83x, an enterprise value of $5.34B, and an EV/EBITDA multiple of 41.80x. On profitability, it posts a gross margin of 100.47%, an operating margin of 32.61%, a net margin of 67.88%, a Return on Equity (ROE) of 21.98%, a Return on Assets (ROA) of 12.58%, and a Return on Invested Capital (ROIC) of 9.59%. Per share, it reports EPS of $9.83, diluted EPS of $9.03, free cash flow per share of $6.55, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 54.89% year-over-year, net income growth of -359.97% year-over-year, and EPS growth of -350.43% year-over-year. On the balance sheet, it maintains a current ratio of 31.18x, a quick ratio of 30.96x, working capital of $1.41B, a debt-to-equity ratio of 1.26x, a debt ratio of 0.56, an interest coverage ratio of 15.30x, free cash flow of $131.44M (TTM), and net debt of $-1.01B. Figures sourced from SEC EDGAR.
- Market Cap
- $6.34B
- P/E TTM
- 32.16x
- EPS TTM
- $9.83
- P/B TTM
- 6.55x
- ROE TTM
- 21.98%
- ROA TTM
- 12.58%
- Debt To Equity
- 1.26x
- Free Cash Flow TTM
- $131.44M
- Net Revenue TTM Growth 1Y
- 54.89%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is LIGAND PHARMACEUTICALS INC in?
LIGAND PHARMACEUTICALS INC (LGND) operates in the Pharmaceutical Preparations industry.
What exchange does LGND trade on?
LIGAND PHARMACEUTICALS INC (LGND) trades on the Nasdaq, OTC.
Where is LIGAND PHARMACEUTICALS INC incorporated?
LIGAND PHARMACEUTICALS INC is incorporated in DE.
When was LIGAND PHARMACEUTICALS INC (LGND)'s most recent SEC filing?
LIGAND PHARMACEUTICALS INC (LGND)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-07.
What is LGND's market cap?
LIGAND PHARMACEUTICALS INC (LGND) has a market capitalization of $6.34B as of 2026-06-30.
What is LGND's P/E ratio?
LIGAND PHARMACEUTICALS INC (LGND)'s trailing twelve month P/E ratio is 32.16x as of 2026-06-30.
What is LGND's EPS (earnings per share)?
LIGAND PHARMACEUTICALS INC (LGND)'s trailing twelve month EPS is $9.83 as of 2026-06-30.
What is LGND's ROE (return on equity)?
LIGAND PHARMACEUTICALS INC (LGND)'s trailing twelve month Return on Equity (ROE) is 21.98% as of 2026-06-30.
What is LGND's ROA (return on assets)?
LIGAND PHARMACEUTICALS INC (LGND)'s trailing twelve month Return on Assets (ROA) is 12.58% as of 2026-06-30.
What is LGND's ROIC (return on invested capital)?
LIGAND PHARMACEUTICALS INC (LGND)'s trailing twelve month Return on Invested Capital (ROIC) is 9.59% as of 2026-03-31.
What is LGND's EV/EBITDA?
LIGAND PHARMACEUTICALS INC (LGND)'s trailing twelve month EV/EBITDA is 41.80x as of 2026-06-30.